Premium
Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma
Author(s) -
Castro Michael P.,
VanAuken Jean,
SpencerCisek Patricia,
Legha Sewa,
Sponzo Robert W.
Publication year - 1999
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19990301)85:5<1055::aid-cncr7>3.0.co;2-3
Subject(s) - medicine , dacarbazine , tumor lysis syndrome , vinblastine , melanoma , oncology , cancer , chemotherapy , alpha interferon , cisplatin , interferon , cancer research , immunology
BACKGROUND Treatment of solid tumors rarely has been associated with tumor lysis syndrome. However, to the authors' knowledge the clinical scenario has not been reported previously in melanoma patients. METHODS A patient with bulky metastatic melanoma was treated with concurrent biochemotherapy using interleukin‐2, interferon‐α, and a combination of cisplatin, vinblastine, and dacarbazine. RESULTS Within 24 hours of the initiation of treatment, brisk tumor lysis occurred and led to a fatal outcome. CONCLUSIONS Improvements in the treatment of solid tumors may increase the incidence of tumor lysis syndrome for tumors once believed to be marginally responsive. Oncologists should remain cognizant of this problem as more active regimens become available. Cancer 1999;85:1055–9. © 1999 American Cancer Society.